Low-molecular-weight heparins (LMWH) represent depolymerized porcine mucosal heparin derivatives, which are commonly used for the management of thrombotic disorders. Because of their widespread usage, the supplies of the raw material namely unfractionated heparin are nearly exhausted. Porcine mucosal tissue is almost exclusively used for the preparation of these agents. Thus, there is a timely need for the production of heparin like drugs from other sources. Fermentation techniques have been used to produce carbohydrates such as dextran and innulin for therapeutic purposes. Bacterial cell wall polysaccharide mimics the linear hexose units, which constitute heparin. Utilizing Escherichia coli cell membranes produced by fermentation technology, chemical sulfation and enzymatic epimerization, sulfaminoheparosan type of polymer mimicking the structure of heparin has been produced. These semi-synthetic sulfaminoheparosans exhibit biologic actions comparable to that observed with heparin. The sulfaminoheparosan core can also be degraded to obtain low-molecular-weight (LMW) derivatives mimicking LMWHs. Using this technique, a novel LMW sulfaminoheparosan derivative (Q93C/239) was produced by Inalco, Milan, Italy. To compare this heparin analogue, a LMWH, namely tinzaparin, was used to determine the relative anticoagulant, antiprotease, and molecular profile. Additional studies were carried out to determine the susceptibility of this agent to heparinase-I. These comparative studies exhibited both antiprotease and anticoagulant properties similar to those of tinzaparin. However LMW sulfaminoheparosan resisted heparinase-I digestion at low heparinase-I concentrations. These studies demonstrate that the sulfaminoheparosan derived LMW components exhibit similar molecular and anticoagulant profile as tinzaparin and warrant additional preclinical and clinical development to determine their potential usefulness as antithrombotic agents.
Thrombotic disorders affect millions of people all over the world each year. Deep venous thrombosis (DVT) alone affects about two million people each year in the United States (1) . Complications of DVT, such as pulmonary embolism, play a role in 50,000 to 250,000 deaths per year. In addition, arterial thrombosis resulting in myocardial infarction and thrombotic stroke results in almost an equal number of deaths per year (2) .
The formation of a blood clot called thrombus inside the blood vessel is referred to as thrombosis. A thrombus can be formed in any blood vessels, such as veins and arteries. The thrombus will eventually lead to the blockage of blood vessel locally or at a distant place. Embolization is the result of mobilization of piece of thrombus through the circulation.
The most widely used drugs available to treat thrombotic disorders are unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH). UFH, considered a first-generation drug, represents a complex mixture of sulfated glycosaminoglycan, which are produced by mammalian connective tissue rich in mast cells. The LMWHs are derived by controlled depolymeriza-27 tion of UFH and are considered a second-generation drug (3) . The market is now increasingly being taken over by the second-generation drugs because of their advantageous pharmacologic profiles and fewer side effects over first-generation drugs.
The primary source for heparins is animal tissue (porcine mucosal tissue and bovine lung tissue). However because of the widespread clinical use of heparin, it is predicted that the raw material used for the production of heparin is likely to be exhausted due to increased demand. In addition, it is complicated to assure safety of animalderived products in clinical use. The above facts led to the attempts to produce heparin-like agents from plants and bacteria (4, 5) .
Razi and coworkers (6) described the generation of series of heparin like compounds also called sulfaminoheparosan analogues (SAH), through regioselective sulfation of capsular polysaccharide from Escherichia coli, K5. The polymeric backbone, known as N-acetyl heparosan, provides a novel starting material to develop heparin-like compounds referred to as semi-synthetic heparin analogues (LMW-SAHs) or SAHs. SAHs can be produced by deacetylation followed by N-sulfation of bacterial capsular polysaccharide (4,7-9). Controlled 0-sulfation of this product, results in the generation of a series of compounds with varying 0-sulfation patterns and anticoagulant activities. A comparison of the disaccharide units of SAHs is shown in Fig. 1 . It is hy-pothesized that these SAHs mimic heparins in exerting the anticoagulant effects and some other biologic actions that are associated with heparins. It is projected that these SAHs may eventually replace heparins to treat thrombotic disorders more effectively and safely.
The aims of the present study are to determine the molecular and pharmacologic profile of a novel LMW bacterial sulfaminoheparosan compared with tinzaparin (10, 11) which is LMW heparin obtaining by heparinase treatment of UFH.
MATERIAL AND METHODS

Materials
The SAH used for this study was a low-molecular-weight sulfaminoheparosan, namely, Q93C/ 239. The material was provided by Ricerche Sperimentali Montale (RSM), Montale, Pistoia, Italy. The material was obtained in the form of powder and stored at room temperature. The LMW-SAH was synthesized by the chemical modifications such as N-deacetylation, N-sulfation, and controlled 0-sulfation and enzymatic epimerization of a polysaccharide from bacterial cell wall E. coli, K5 (4, 6, 12, 13) .
The comparative drug was Tinzaparin, a commercially available LMWH prepared by heparinase-I digestion of porcine mucosal heparin. This drug is commercially available in the United States for the treatment of DVT ( Pharmion Corp., Boulder, Colorado). 
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PROFILE OF LOW-MOLECULAR-WEIGHT BACTERIAL SULFAMINOHEPAROSAN
A comparison of the properties of the two agents is given in Table 1 . Although the two agents are prepared by different methods, their molecular profiles and anticoagulant potencies were comparable.
Molecular Profiling
The molecular weight (MW) determinations were performed by using gel permeation chromatography and high-performance liquid chromatography (GPC-HPLC) system. The GPC-HPLC system was equipped with the software Millennium32 2000 for the analysis of the data. The system contains a computer (Intel Inside, Pentium IV), Waters 600 Controller, and a Water 717plus autosampler. The ultraviolet (Waters 2487 Dual X Absorbance Detector) and refractive index (Waters 2414 Refractive Index Detector) detectors were linked with the joint columns (TSK G3000 and TSK G2000SW) attached to UV detector (12) . The method developed by Ahsan and associates (14) was followed to determine the molecular profile of LMW-SAHs. The samples were prepared by adding 10 mg of the drug to 1 mL of 0.3M sodium sulfate (pH adjusted to 5.0) to get the concentration of 10 mg/mL. Thirty microliters of each sample was injected into the GPC-HPLC system. The sample was run at steady flow rate of 0.5 mL/min of 0.3M sodium sulfate that is referred to as mobile phase. The run time was 65 minutes. Both LW and RI determinations were made at 205 nm at room temperature. Similar to the report from Ahsan (14) , narrow range calibration (NRC) method was used to analyze molecular profile of these samples.
Susceptibility to Heparinase-I
The molecular profile was also carried out after heparinase-I digestion of each of these agents (15) . Heparinase-I was obtained from IBEX Corp., Montreal, Canada.
Each of these agents were prepared at a concentration of 10 mg/mL of sodium sulfate at 0.3M (pH adjusted to 5). Ten microliters of heparinase-I (1 U/mL of final concentration) was added to 90 /iL of each agent and was incubated for 30 minutes at 37°C. The incubated samples were then heat treated (placed in boiling water at 100°C) for 2 minutes to arrest the enzymatic activity. Thirty microliters of each sample was then injected in to GPC-HPLC system.
Biologic Profiles
The in vitro anticoagulant, antiprotease, and protease generation inhibition properties of tin- zaparin and SAH were determined by the standard clot-based assays such as activated partial thromboplastin time (aPTT), Heptest®, and thrombin time (5U TT). The chromogenic assays for anti-FXa and anti-FIIa activities were performed using amidolytic methods. The agents prepared at the concentration of 10 mg/mL in 0.3M sodium sulfate were diluted to the stock concentration of 1 mg/mL using saline. The agents (at the concentration of 1 mg/mL) were then supplemented to pooled normal human plasma (NHP) at the ratio of 1:10 to make a final concentration of 100 ,ug/mL and serially diluted to 0.8 ,tug/mL.
aPTT
The aPTT test was performed using platelin reagent from Biomeriux. One hundred microliters of plasma supplemented with each of these agents was equilibrated at 37°C. One hundred microliters of aPTT reagent was then added. After 5 minutes of incubation, calcium was added to trigger coagulation. The clotting times were measured using a Fibrometer®.
Heptest®
Heptest® (Haemachem, St.Louis, MO) is a clot-based assay used to measure the clotting times after the addition of purified bovine factor Xa. To perform this assay, 100 ,uL of plasma containing each agent was added to 100 ,uL of bovine factor Xa and incubated for 2 minutes at 37°C. The clotting times were measured by using Fibrometer® after the addition of 100 AL of prewarmed Recalmix®. The clotting times above 300 seconds were not considered because they are out of the linear range of the assay. 29 
Anti-Factor Xa Assay
The anti-Xa potency of both tinzaparin and LMW-SAH was determined by using the chromogenic assay anti-FXa assay. This assay was performed using ACL 300 Plus (Automated Coagulation Laboratory, Beckman-Coulter, Miami, FL). Ten microliters of drug sample (in NHP) was added to 100 AL of bovine factor Xa (Enzyme Research Laboratory, South Bend, IN) and incubated for 2 minutes and then 75 ALL of Spectrozyme® FXa (American Diagnostica Inc., Greenwich, CT) was added. The percent inhibition of the factor Xa was calculated by using the following formula:
Anti-Factor IIa Assay
The in vitro anticoagulant profiles of tinzaparin and LMW-SAH on factor IIa inhibition were measured by a chromogenic anti-factor IIa assay. This assay was performed on ACL 300 Plus. Ten microliters of each sample (in NHP) was added to 100,LL of thrombin (10 U/mL) and incubated for 15 seconds. Then 40 ALL of Spectrozyme®TH (American Diagnostica Inc., Greenwich, CT) was added. The percent inhibition of factor Ila was calculated by reading optical density of the drug sample compared to the optical density of NHP. The same formula, which was used to calculate the percent inhibition of FXa generation, was used.
Thrombin and FXa Generation Inhibition Assay
The thrombin and Xa generation inhibition assays were performed on human fibrinogen-depleted plasma. Each of these agents was supplemented in a concentration range of 0 to 100 A,g/mL. Plasma samples were then activated by diluted PT (Thromboplastin C) and aPTT (Dade® Actin) reagents. The generation of Xa and thrombin was monitored using a centrifugal kinetic analyzer (ACL 300 Plus).
RESULTS
Molecular Profile
The results of the comparative molecular profile of tinzaparin in terms of elution profile are given in Fig. 2 . As can be seen in this figure, the elution profile of both the agents was similar. Tinzaparin exhibited molecular characteristics of a LMWH where the oligosaccharide peaks were distinct in the low-molecular-weight range. However, this was not true for LMW-SAH. Comparative Digestion of Tinzaparin and LMW-SAH Fig. 3 shows the molecular profile of the two agents after the heparinase-I digestion. Distinct peaks representing di, tetra, hexa, octa, and decasaccharides were evident in the case of tinzaparin. No disaccharide formation was seen with LMW-SAH. Except for these changes, the molecular profile of the digested products was about the same. Table 2 shows a quantitative comparison of the molecular components of the two agents before and after the heparinase-I digestion. Even at ten times of higher concentration of heparinase-I the LMW-SAH did not show any significant changes in oligosaccharide distribution.
The prevalence of > 5,000 Da molecular weight (MW) components of LMW-SAH was 51% and < 5,000 Da was 49% before heparinase-I digestion. The MW components of > 5,000 Da represented 49% and < 5,000 Da was 51% post heparinase-I digestion.
Tinzaparin, however, showed a significant digestion at 0.1 U/mL of heparinase-I. The prevalence of >5,000 Da MW components of Tinzaparin was 59% and < 5,000 Da was 41% before heparinase-I digestion. The prevalence of > 5000 Da MW components was 43% and < 5,000 Da was 57% after the heparinase-I digestion, suggesting a decrease in MW. Clot-Based Assays: Anticoagulant Effects Fig. 4 shows the comparative anticoagulant effects of the agents in aPTT test. In a concentration range of 0 to 5 ,ug/mL both drugs produced a similar concentration dependent increase. At higher concentrations tinzaparin showed a slightly higher anticoagulant effect. A prolongation of aPTT to 100 seconds was achieved for tinzaparin at 8,tg/mL, whereas SAH produced comparable effect at 10.4,ug/mL.
As shown in Fig. 5 , in the Heptest' assay both agents produced concentration dependence in the clotting time. Tinzaparin showed a slightly higher effect prolonging the Heptest® time to seconds at 7,g/mL where as similar prolongation for SAH was shown at 10.2,g/mL.
As seen in Fig. 6 , both tinzaparin and LMW-SAH produced a strong anticoagulant effect in the thrombin time assay. In this assay tinzaparin showed a much stronger anticoagulant effect. Prolongation of the clotting time to 100 seconds was seen at 2 ,ug/mL for tinzaparin and similar effect was observed at 3.8 ,ukg/mL for LMW-SAH.
Antiprotease Effects
As shown in Fig. 8 , both agents were able to produce a concentration-dependent inhibition of factor Xa that reached a near maximum at con- centration of approximately 10 ,ug/mL. The inhibitory pattern was similar for both of these agents.
Tinzaparin, however, was found to be a stronger inhibitor (IC50 = 2 ,ug/mL) in comparison to LMW-SAH (IC50 = 3.6 ,tg/mL).
As shown in Fig. 7 , both of these agents were also found to inhibit thrombin at a relatively weaker level in comparison to the inhibition of factor Xa. The IC.0 of tinzaparin was found to be 4.2 Aug/mL, whereas the IC50 of LMW-SAH was found to be 6.6,g/mL. 
Protease Generation Inhibition Studies
The protease generation inhibition studies were carried out in fibrinogen depleted plasma supplemented with both agents at a concentration of 0 to 100 ,g/mL. Thrombin and factor Xa generation was monitored using amidolytic methods and extrinsic (Thromboplastin® C plus) and intrinsic (Platelin®) activation. Fig. 9 shows the results of inhibition of factor Xa generation inhibition in the extrinsic system. In this study SAH was found to be a much stronger inhibitor than tinzaparin. The IC50 of both of these agents were below 5 ,ug/mL. More interestingly, as shown in Fig. 10 , in the extrinsic system the thrombin generation inhibition was only seen with the SAH and not with tinzaparin. The IC50 of LMW-SAH for this action was less than 2 /.g/mL. As depicted in Fig. 11 , in the intrinsic system, for the factor Xa generation both agents produced a concentration-dependent inhibition of factor Xa. However, LMW-SAH produced much stronger inhibition (IC50 = 10 ,ug/mL) in contrast to tinzaparin (IC50 = 40 t.g/mL). Similarly, in the intrinsic system, SAH produced much stronger inhibition of thrombin (IC50 = 18 ,ug/mL) in contrast to Tinzaparin (IC50 > 100 Aug/mL) as shown in Fig.   12 . These data suggest that LMW-SAH is a much more potent inhibitor of protease generation. Table 3 shows a comparison of the potency of LMW-SAH and tinzaparin. In the clotting assays LMW-SAH was found to be slightly weaker. This clearly indicated that the inhibitory actions of this agent were weaker. Similarly, in the amidolytic assays, SAH was weaker. However, in protease generation inhibition assays, SAH was markedly stronger than tinzaparin.
DISCUSSION
The need for a heparin substitute is timely because of the limitation of the raw material used for the production of heparin. The LMWHs are almost exclusively prepared by using porcine mucosal heparin. As the demand for these agents has greatly increased, the supply of the raw material is proportionally diminished. Furthermore, the problem associated with viral contamination and marked batch variations have contributed to the problems related to the development of LMWHs. There are also considerable differences in the quality of heparin raw material from different countries. This contributes to the major variations, which are observed with the specific potency of LMWHs. Biotechnologically derived proteins have contributed significantly to the development of new drugs (4, 6) . Such drugs such as insulin, recombinant factor VIII, growth factors and erythropoietin are some examples. Fermentation technology has been used in the production of carbohydrate-derived drugs such as inulin, dextran sulfate, and carboxymethyl cellulosederived drugs. The identification of hexose polymers of the K5 family enabled industry to use syntheticand biotechnology-based methods to transform these polymers in to heparin analogs (4) . While the parent product exhibit molecular weight >20,000 Da, these agents can be depolymerized to obtain low-molecularweight sulfaminoheporasan derivatives with desirable molecular weight. The agent used in the current studies represent a novel low-molecularweight SAH with molecular and biochemical characteristics similar to those of commercially available LMWHs. For this reason, a direct comparison of this agent was made with tinzaparin, which is a commercially available LMWH with molecular characteristics similar to those of LMW-SAH. Tinzaparin is relatively stronger anticoagulant in comparison to other LMWHs.
Thus, the characteristics of LMW-SAH are within the biologic profile of other LMWHs.
In this study, the molecular profile of SAH was found to be comparable to that of tinzaparin. However, in contrast to tinzaparin, SAH was found to be resistant to the depolymerization effects of heparinase-I (16) . This may be due to the differences in the disaccharide composition of these agents. Tinzaparin at a much lower heparinase-I concentration was digested whereas SAH resisted the digestion by the enzyme.
The anticoagulant actions of SAH were comparable to those of tinzaparin in the aPTT. All results are converted as /og/mL. However, tinzaparin was slightly stronger in most of these assays. This suggested that both agents inhibit the intrinsic pathway of coagulation. Both agents also inhibited the Heptest® clotting time indicating their anti-Xa actions. Each of these agents produced a strong effect on the thrombin time prolongation indicating their inhibitory effect on thrombin. Tinzaparin consistently produced stronger effects in all of these assays. Both agents produced inhibition of Xa and Ila factors. The relative inhibition of Xa was stronger. Tinzaparin produced a consistently stronger inhibition in both assays than SAH. The IC50 of SAH was nearly double that of tinzaparin. These data clearly suggest that SAH may have affinity to both the antithrombin-III and heparin cofactor-II (13) .
Interestingly, in the protease generation inhibition studies SAH produced consistently much stronger inhibition of both factor Xa and IIa generation in the intrinsic and extrinsic pathways. More interestingly, in the protease generation inhibition assays in both intrinsic and extrinsic pathways tinzaparin did not produced a significant inhibition. This clearly suggests that SAH is much more potent inhibitor of protease generation.
While the LMW-SAH exhibited slightly weaker effects in the anticoagulant and antiprotease assays in comparison to tinzaparin, the fact that this agent is a potent inhibitor of protease generation and is not digested by heparinase-I suggests that it might have pharmacologically equivalent or better antithrombotic profile to that of tinzaparin.
However, to have a comprehensive profile of this new compound, additional studies are needed to determine its interaction with platelets and other blood cells. These studies therefore warrant additional preclinical studies including animal models for demonstrating its antithrombotic and hemorrhagic profiles.
